Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Accounts Payables (2016 - 2026)

Sunshine Biopharma filings provide 14 years of Accounts Payables readings, the most recent being $5.7 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 2.19% to $5.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.7 million, a 2.19% increase, with the full-year FY2025 number at $5.7 million, up 2.19% from a year prior.
  • Accounts Payables hit $5.7 million in Q4 2025 for Sunshine Biopharma, down from $6.1 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $6.1 million in Q3 2025 to a low of $42942.0 in Q4 2021.
  • Median Accounts Payables over the past 5 years was $2.7 million (2023), compared with a mean of $2.7 million.
  • The widest YoY moves for Accounts Payables: up 6426.94% in 2022, down 35.9% in 2022.
  • Sunshine Biopharma's Accounts Payables stood at $42942.0 in 2021, then skyrocketed by 6426.94% to $2.8 million in 2022, then fell by 7.75% to $2.6 million in 2023, then surged by 114.39% to $5.5 million in 2024, then grew by 2.19% to $5.7 million in 2025.
  • The last three reported values for Accounts Payables were $5.7 million (Q4 2025), $6.1 million (Q3 2025), and $4.8 million (Q2 2025) per Business Quant data.